NCT05066412招募中1 期
A Phase I Clinical Trial Assessing Prophylactic Donor CD45RA-depleted Lymphocyte Infusions Into Patients Transplanted with Stem Cell Grafts from Haploidentical Donors After Reduced Intensity Conditioning
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- acute transfusion reaction (CTCAE ≥ 2)
研究概览
简要总结
To assess safety of prophylactic escaladed dose of T naïve depleted (CD45RA depleted donor lymphocyte infusion, in patients with malignant hemopathie who received an allogeneic stem cell transplant from an haplo-identical donor, after a reduced intensity conditionning regiment.
详细描述
Primary Objective is to determine whether the administration of prophylactic CD45RAneg (CD45RAneg) memory/effector T lymphocytes is feasible and safe in the early post-transplant period for patients with haploidentical transplant and RIC conditioning.
Donor lymphocytes are isolated from the original donor by non-mobilized mononuclear cell leukapheresis. Repetitive intravenous infusions (up to 3) of escalating doses of CD45RAneg cells, prepared from the leukapheresis by CliniMACS® technology (CD45RA-depletion), storage in vapor nitrogen.
Escalating doses of CD45RAneg cells, for patients with haploidentical graft, intervals of 6-8 weeks, if GvHD is absent starting ≥ 4 weeks from the day of transplantation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients who received a stem cell graft from a haploidentical donor after RIC for hematologic malignancies
- •Written informed consent of patient and donor obtained
排除标准
- •Participant taking Prednisone (or equivalent steroid)
- •Participant taking Prednisone (or equivalent steroid)
- •Participant taking Mycophenolate Mofetil
- •Participant taking Cyclosporine/tacrolimus at therapeutic blood levels
- •Progressive hematologic malignancy before transplant
- •Second allogeneic transplant
- •Acute GvHD ≥ grade 2
- •Chronic moderate or severe GvHD (NIH consensus criteria)
- •Hematologic or molecular relapse of the primary malignancy requiring chemotherapy or unmanipulated DLI (receiving prophylactic antileukemic agent, eg TKI, is not an exclusion criteria)
- •Donor aberrant CD45RA expression due to a polymorphism in CD45 gene
- •Participation in another interventional clinical trial within 30 days prior to inclusion
- •Pregnant or nursing women. Sexually active women with childbearing potential as well as sexually active male patients who are unwilling to use an effective method of contraception during participation in the study from time of inclusion until 2 months after last dose of CD45RAneg DLI infusion
- •Inability to follow the procedures of the study, including, but not limited to, language problems, psychological disorders, dementia
研究组 & 干预措施
Arm 1
Experimental
Prophylactic CD45RA-depleted DLI
干预措施: CD45RAneg cells, prepared from mononuclear cell leukapheresis by CliniMACS® technology (Other)
结局指标
主要结局
acute transfusion reaction (CTCAE ≥ 2)
时间窗: 24 hours after each CD45RA neg DLI infusion
acute transfusion reaction after each DLI infusion (CTCAE ≥ 2)
acute GvHD grade II-IV
时间窗: within 8 weeks after each CD45RAneg DLI infusion
acute GvHD grade II-IV measured with MAGIC score
次要结局
未报告次要终点
研究者
Anne-Claire Mamez
Principal Investigator
University Hospital, Geneva
研究点 (1)
Loading locations...
相似试验
招募中
1 期
CD45RA Depleted DLI After TCRα/β Depleted Haploidentical HCTHematologic MalignancyNCT05943067University Hospital Tuebingen60
已完成
2 期
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Childhood Nasal Type Extranodal NK/T-cell LymphomaExtranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid TissueRecurrent Adult Acute Myeloid LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Hairy Cell LeukemiaSecondary Myelodysplastic SyndromesAdult Acute Myeloid Leukemia With t(15;17)(q22;q12)Childhood Burkitt Lymphomade Novo Myelodysplastic SyndromesIntraocular LymphomaNoncutaneous Extranodal LymphomaAnaplastic Large Cell LymphomaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Nasal Type Extranodal NK/T-cell LymphomaBlastic Phase Chronic Myelogenous LeukemiaChildhood Immunoblastic Large Cell LymphomaPeripheral T-cell LymphomaRecurrent Adult Burkitt LymphomaRecurrent Adult Lymphoblastic LymphomaAccelerated Phase Chronic Myelogenous LeukemiaAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Angioimmunoblastic T-cell LymphomaChronic Phase Chronic Myelogenous LeukemiaCutaneous B-cell Non-Hodgkin LymphomaHepatosplenic T-cell LymphomaNodal Marginal Zone B-cell LymphomaChildhood Chronic Myelogenous LeukemiaChildhood Diffuse Large Cell LymphomaChildhood Myelodysplastic SyndromesPreviously Treated Myelodysplastic SyndromesRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Childhood Acute Lymphoblastic LeukemiaRecurrent Childhood Small Noncleaved Cell LymphomaRecurrent Cutaneous T-cell Non-Hodgkin LymphomaPost-transplant Lymphoproliferative DisorderRecurrent Adult Acute Lymphoblastic LeukemiaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Hodgkin LymphomaRecurrent Adult T-cell Leukemia/LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaSplenic Marginal Zone LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Grade III Lymphomatoid GranulomatosisRecurrent Adult Immunoblastic Large Cell LymphomaRecurrent Childhood Anaplastic Large Cell LymphomaRecurrent Childhood Grade III Lymphomatoid GranulomatosisRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRecurrent Mycosis Fungoides/Sezary SyndromeRefractory Chronic Lymphocytic LeukemiaRelapsing Chronic Myelogenous LeukemiaSmall Intestine LymphomaT-cell Large Granular Lymphocyte LeukemiaTesticular LymphomaWaldenström MacroglobulinemiaRecurrent Childhood Acute Myeloid LeukemiaRecurrent Childhood Large Cell LymphomaRecurrent Childhood Lymphoblastic LymphomaRecurrent Grade 2 Follicular LymphomaRecurrent/Refractory Childhood Hodgkin LymphomaNCT01839916University of Chicago77
进行中（未招募）
1 期
T-Cell Therapy for Advanced Breast CancerMetastatic HER2-negative BreastBreast CancerNCT02792114Memorial Sloan Kettering Cancer Center186
已完成
1 期
Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell TransplantationOpportunistic InfectionsGraft vs Host DiseaseImmune Deficiency DiseaseBone Marrow Failure SyndromesPrecursor T-Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myeloid, AcuteNCT02337595Federal Research Institute of Pediatric Hematology, Oncology and Immunology30
已完成
2 期
Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in ChildrenAccelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Biphenotypic LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent Adult Acute Lymphoblastic LeukemiaRefractory Childhood Acute Lymphoblastic LeukemiaAcute Leukemia of Ambiguous LineageAdult Acute Myeloid Leukemia in RemissionChildhood Acute Lymphoblastic Leukemia in RemissionRecurrent Adult Acute Myeloid LeukemiaRecurrent Childhood Acute Lymphoblastic LeukemiaChronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent Childhood Acute Myeloid LeukemiaChildhood Acute Myeloid Leukemia in RemissionMyelodysplastic Syndrome With Excess Blasts-1Myelodysplastic Syndrome With Excess Blasts-2Refractory Adult Acute Lymphoblastic LeukemiaAcute Undifferentiated LeukemiaNCT01858740Fred Hutchinson Cancer Center20